Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574743 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT00574743 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 162 participants.
The verdict
NCT00574743, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of EC-MPS (ERL080) in comparison to MMF in de novo heart recipients.
Interventions
- DRUG Enteric-coated Mycophenolate Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2002-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574743
The ClinicalTrials.gov registry entry for NCT00574743 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enteric-coated Mycophenolate Sodium is the first listed.
NCT00574743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574743 about?
NCT00574743 is a clinical study titled "Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients". This study will evaluate the safety and efficacy of EC-MPS (ERL080) in comparison to MMF in de novo heart recipients.
What is the current status of trial NCT00574743?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2002-01.
What interventions are being tested in trial NCT00574743?
The interventions under investigation include: Enteric-coated Mycophenolate Sodium (DRUG).
Who is sponsoring clinical trial NCT00574743?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.